Axsome Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2012-01-01
- Employees
- 545
- Market Cap
- $4.2B
- Website
- http://www.axsome.com
- Introduction
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview contain AXS-05, AXS-07, AXS-12, and ...
An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects with Dementia of the Alzheimer's Type, ADVANCE-2 and ACCORD-2 Extension Study
- First Posted Date
- 2024-12-16
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Axsome Therapeutics, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT06736509
- Locations
- 🇵🇷
Clinical Research Site, San Juan, Puerto Rico
Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)
- Conditions
- Interventions
- First Posted Date
- 2024-08-23
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Axsome Therapeutics, Inc.
- Target Recruit Count
- 520
- Registration Number
- NCT06568367
- Locations
- 🇺🇸
Clinical Research Site, San Antonio, Texas, United States
Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol
- Conditions
- Interventions
- First Posted Date
- 2024-05-14
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- Axsome Therapeutics, Inc.
- Target Recruit Count
- 450
- Registration Number
- NCT06413433
- Locations
- 🇺🇸
Clinical Research Site, San Antonio, Texas, United States
SUNOSI® (Solriamfetol) Pregnancy Registry
- First Posted Date
- 2024-05-14
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- Axsome Therapeutics, Inc.
- Target Recruit Count
- 1731
- Registration Number
- NCT06413420
- Locations
- 🇺🇸
Evidera, a PPD business unit, Morrisville, North Carolina, United States
🇺🇸PPD, Inc., Wilmington, North Carolina, United States
Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using Solriamfetol
- Conditions
- Interventions
- First Posted Date
- 2024-04-11
- Last Posted Date
- 2024-04-11
- Lead Sponsor
- Axsome Therapeutics, Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT06360419
- Locations
- 🇺🇸
Clinical Research Site, Everett, Washington, United States
A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
- First Posted Date
- 2024-01-25
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- Axsome Therapeutics, Inc.
- Target Recruit Count
- 350
- Registration Number
- NCT06223880
- Locations
- 🇺🇸
Clinical Research Site, Everett, Washington, United States
A Study to Access the Efficacy and Safety of Solriamfetol in Subjects With ADHD (FOCUS)
- Conditions
- Interventions
- First Posted Date
- 2023-08-02
- Last Posted Date
- 2024-04-26
- Lead Sponsor
- Axsome Therapeutics, Inc.
- Target Recruit Count
- 450
- Registration Number
- NCT05972044
- Locations
- 🇺🇸
Clinical Research Site, Everett, Washington, United States
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects with Alzheimer's Disease Agitation
- Conditions
- Interventions
- First Posted Date
- 2022-09-28
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Axsome Therapeutics, Inc.
- Target Recruit Count
- 350
- Registration Number
- NCT05557409
- Locations
- 🇵🇷
Clinical Research Site, San Juan, Puerto Rico
Open-Label Study of AXS-07 for the Acute Treatment of Migraine in Adults With a Prior Inadequate Response to an Oral CGRP Inhibitor (EMERGE)
- First Posted Date
- 2022-09-22
- Last Posted Date
- 2024-04-26
- Lead Sponsor
- Axsome Therapeutics, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT05550207
- Locations
- 🇺🇸
Clinical Research Site, McLean, Virginia, United States
A Study to Assess the Long-term Efficacy and Safety of AXS-12 (Reboxetine) in Subjects with Narcolepsy (ENCORE)
- Conditions
- Interventions
- First Posted Date
- 2021-11-09
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Axsome Therapeutics, Inc.
- Target Recruit Count
- 68
- Registration Number
- NCT05113745
- Locations
- 🇨🇦
Clinical Research Site, Toronto, Ontario, Canada